Polaryx Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • PLYX

Stock Symbol

  • Share Price
  • $1.32
  • (As of Friday Closing)

Polaryx Therapeutics General Information

Description

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Contact Information

Website
www.polaryx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 140 East Ridgewood Avenue, South Tower
  • Suite 415
  • NJ 07652
  • United States
+1 (201)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 140 East Ridgewood Avenue, South Tower
  • Suite 415
  • NJ 07652
  • United States
+1 (201)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Polaryx Therapeutics Stock Performance

As of 20-Nov-2026, Polaryx Therapeutics’s stock price is $1.32. Its current market cap is $66.3M with 49.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.32 $1.51 $1.30 - $48.91 $66.3M 49.8M 37.7K -$0.18

Polaryx Therapeutics Financials Summary

As of 30-Sep-2026, Polaryx Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 91,639
Revenue 0 0 0 0
EBITDA (8,747) (8,985) (30,356) (3,779)
Net Income (8,747) (8,985) (30,356) (3,779)
Total Assets 8,610 5,170 5,001 2,315
Total Debt 128
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Polaryx Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Polaryx Therapeutics‘s full profile, request access.

Request a free trial

Polaryx Therapeutics Patents

Polaryx Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260027048-A1 Gemfibrozil formulation Pending 03-Jun-2022
WO-2023235541-A1 Gemfibrozil formulation Inactive 03-Jun-2022
AU-2021224133-A1 Gemfibrozil formulation Active 19-Feb-2020
AU-2021224133-B2 Gemfibrozil formulation Active 19-Feb-2020
CA-3168470-A1 Gemfibrozil formulation Pending 19-Feb-2020 A61K31/192
To view Polaryx Therapeutics’s complete patent history, request access »

Polaryx Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Polaryx Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Polaryx Therapeutics’s complete esg history, request access »

Polaryx Therapeutics FAQs

  • When was Polaryx Therapeutics founded?

    Polaryx Therapeutics was founded in 2014.

  • Where is Polaryx Therapeutics headquartered?

    Polaryx Therapeutics is headquartered in NJ.

  • What is the size of Polaryx Therapeutics?

    Polaryx Therapeutics has 11 total employees.

  • What industry is Polaryx Therapeutics in?

    Polaryx Therapeutics’s primary industry is Drug Discovery.

  • Is Polaryx Therapeutics a private or public company?

    Polaryx Therapeutics is a Public company.

  • What is Polaryx Therapeutics’s stock symbol?

    The ticker symbol for Polaryx Therapeutics is PLYX.

  • What is the current stock price of Polaryx Therapeutics?

    As of 20-Nov-2026 the stock price of Polaryx Therapeutics is $1.32.

  • What is the current market cap of Polaryx Therapeutics?

    The current market capitalization of Polaryx Therapeutics is $66.3M.

  • What is Polaryx Therapeutics’s annual earnings per share (EPS)?

    Polaryx Therapeutics’s EPS for 12 months was -$0.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process